VTR Chart

1 Month

	Date	Diff
	2025-05-02	+1.56 %
The article reports on a class action securities lawsuit filed against Viatris Inc. (NASDAQ: VTRS) over alleged securities fraud, which caused a significant drop in the company's stock price following disappointing financial guidance related to a warning letter from the FDA. The 1.56% increase in VTR stock last night could be attributed to a market rebound or investor sentiment recovering after the initial drop, or a response to broader market trends rather than specific news about Viatris.
	2025-05-01	-6.48 %
Ventas (VTR) stock was down 6.48% following the announcement of a lawsuit against Viatris Inc. and its executives for alleged securities fraud related to misleading statements about the company's operational status and the adverse effects of a failed FDA inspection at its facility in India, which is expected to significantly impact revenue and earnings. Ventas, Inc. (NYSE: VTR) stock experienced a drop of 6.48% after reaching a new 52-week high previously, likely due to profit-taking by investors following a strong earnings report, along with insider selling that may have raised concerns among shareholders. Ventas (VTR) stock experienced a decline of 6.48% due to the announcement of disappointing financial results and guidance from Viatris Inc., which was involved in a securities class action lawsuit for failing to disclose material information. Ventas (VTR) stock declined by 6.48% due to concerns regarding the impact of a recent FDA warning letter related to its Indore, India facility, which affected investor confidence and led to disappointing financial guidance.
	2025-04-30	+1.36 %
Ventas (VTR) stock increased by 1.36% likely as a reaction to the growing interest in a securities class action lawsuit against Viatris Inc., which prompted investors to reevaluate related investments.
	2025-04-29	+0.93 %
Ventas (VTR) stock rose by 0.93% following news of a class action lawsuit against Viatris, Inc., indicating potential market reactions to legal developments rather than direct implications for VTR itself. The article discusses a class action securities lawsuit against Viatris Inc. related to alleged securities fraud, which has impacted the company's stock performance, leading to a recent decline before a slight recovery. The reason for the recent increase in Viatris (VTRS) stock, which was up 0.93%, may stem from potential optimism from investors regarding the lawsuit and its implications, or a broader market trend affecting stock prices positively. Ventas (VTR) stock rose by 0.93% last night following a broader context of legal scrutiny regarding Viatris, Inc., which may have led to increased investor interest or confidence in VTR as a separate entity from the troubled Viatris, despite the latter's declining stock performance due to disappointing financial guidance related to operational issues and regulatory challenges. Ventas (VTR) stock rose by 0.93% due to positive market sentiment and analysts' ratings, with increased investments from major institutional investors indicating confidence in the stock's future performance.
	2025-04-28	+0.5 %
The article discusses a notice from The Gross Law Firm regarding class action proceedings for shareholders of Viatris Inc. (VTRS), following a significant drop in stock price due to misleading statements about the impact of a warning letter from the FDA on the company's operations, while the stock for Ventas, Inc. (VTR) rose by 0.5% for reasons not explicitly mentioned in the article. The increase in Ventas (VTR) stock could be attributed to market trends, positive investor sentiment, or broader economic factors that were not detailed in the article.
	2025-04-25	-0.37 %
Ventas (VTR) stock declined by 0.37% due to the fallout from a lawsuit against Viatris Inc. for potential securities law violations related to issues at its manufacturing facility, which led to significant financial repercussions and operational challenges for the company. Ventas (VTR) stock fell by 0.37% due to broader market reactions linked to Viatris's recent class action lawsuit and disappointing financial performance, which includes missed earnings estimates and lowered guidance, affecting investor sentiment. Ventas (VTR) stock fell by 0.37% last night, likely due to its less favorable comparative performance against HA Sustainable Infrastructure Capital in key investment metrics such as revenue, potential for growth, and analysts' recommendations.
	2025-04-24	-0.34 %
The article discusses a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to alleged securities fraud that has negatively impacted the company's stock, which fell substantially due to misrepresentations regarding a warning letter from the FDA concerning its Indore, India facility. The decline in stock price is primarily attributed to Viatris' poor financial guidance linked to the impact of this warning letter and import alert. Ventas (VTR) stock declined by 0.34% due to disappointing fiscal guidance and material disclosures related to a securities class action lawsuit against Viatris Inc. for not revealing significant information during the class period, which negatively impacted investor confidence.
	2025-04-23	+0.51 %
Ventas (VTR) stock rose by 0.51% amidst ongoing legal issues faced by Viatris Inc., which has been sued for potential securities law violations related to a failed FDA inspection that negatively impacted its financial outlook. Viatris Inc. (NASDAQ:VTRS) stock increased by 0.51% as it is recognized as one of the best cheap stocks to buy under $10, showing strong growth potential through its diverse healthcare offerings and significant new product revenues, coupled with positive market sentiment amid recent discussions about potential easing of economic uncertainties. The increase in Viatris (VTRS) stock can be attributed to its strong financial performance indications, ongoing product development, and the broader positive market trends discussed by analysts. The article discusses an investigation into Viatris, Inc. (VTRS) by Faruqi & Faruqi LLP regarding potential securities law violations and lawsuits following a significant drop in the company's stock price due to disappointing financial guidance after an FDA warning letter. Ventas (VTR) stock's recent 0.51% increase could potentially be attributed to investor sentiment stabilizing after previous declines linked to the announcement of the class action lawsuit against Viatris rather than specific positive news regarding Ventas itself. Ventas (VTR) stock recently increased by 0.51%, likely due to positive sentiment surrounding its performance compared to other inexpensive stocks and the overall market outlook. The article discusses a notice issued by The Gross Law Firm to shareholders of Viatris Inc. (NASDAQ: VTRS), who may be eligible to participate in a class-action lawsuit due to allegedly misleading statements made by the company's management regarding regulatory issues, which contributed to a significant stock price drop following disappointing financial results. Ventas (VTR) stock was not mentioned in relation to a reason for its increase; however, if it went up, it could be attributed to broader market trends or investor reactions to different news, as the article focuses primarily on Viatris (VTRS) and its legal situation.
	2025-04-21	-1.65 %
The article reports on a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) related to allegations of securities fraud, which has contributed to a significant decline in its stock price; specifically, the stock fell approximately 15.21% following disappointing financial results linked to regulatory issues with the company's Indore, India facility, leading to a -1.65% drop in VTR's stock. The decline in the stock is primarily attributed to concerns surrounding a warning letter from the FDA regarding Viatris' Indore facility, which was downplayed by the company and ultimately impacted its financial guidance negatively, resulting in a sharp drop in stock value. Ventas, Inc. (NYSE: VTR) stock decreased by 1.65% after Guggenheim Capital LLC significantly reduced its holdings in the company by 76.1%, alongside other institutional investor activity that may have contributed to market sentiment affecting the stock. Ventas (VTR) stock fell by 1.65% in response to a lawsuit filed against Viatris Inc. for potential federal securities law violations related to the company's misleading statements about its operations following a failed FDA inspection that significantly impacted its revenue and earnings projections. Ventas (VTR) stock decreased by 1.65% amid concerns surrounding a class action lawsuit against Viatris, Inc. related to securities fraud and disappointing financial results, including lower-than-expected guidance and issues with a manufacturing facility. The article reports that Viatris, Inc. (NASDAQ: VTRS) experienced a decline of 1.65% in its stock price due to the announcement of a class action lawsuit alleging securities fraud and the company's poor financial performance and lowered guidance for 2025.
	2025-04-17	+0.44 %
The article discusses a class action lawsuit filed against Viatris, Inc. (NASDAQ: VTRS) alleging securities fraud, following disappointing financial results and lower guidance for 2025, which previously caused the stock price to drop significantly. Ventas (VTR) stock may have risen by 0.44% due to broader market trends or specific investor sentiment, rather than being directly related to the issues faced by Viatris. Ventas (VTR) stock rose by 0.44% last night as it continues to attract interest from institutional investors and analysts, particularly following positive earnings results and a dividend increase. Ventas (VTR) stock rose by 0.44% due to investor optimism following a lawsuit announcement against Viatris Inc. for securities law violations, which may indicate a perception of potential legal repercussions impacting Viatris negatively in the market and indirectly benefiting related stocks. Ventas (VTR) stock rose by 0.44% following the announcement of a securities class action lawsuit against Viatris, which may have prompted investor interest and optimism amidst the ongoing situation. Ventas (VTR) stock was up 0.44% due to increased investor interest in response to the upcoming June 3, 2025 deadline for filing claims related to a class action lawsuit against Viatris Inc., which has implications for investor confidence and market activity.
	2025-04-16	-0.22 %
Ventas (VTR) stock decreased by 0.22% due to the filing of a securities class action lawsuit against Viatris Inc. for failing to disclose material information, combined with disappointing financial guidance announced by the company, which negatively affected investor sentiment. Ventas (VTR) stock experienced a decline of 0.22%, likely influenced by broader market trends and negative developments related to Viatris, which includes missed earnings expectations and decreased guidance for future performance. Ventas (VTR) stock was down 0.22% following the announcement of a class action lawsuit against Viatris Inc. (VTRS) for allegedly misleading investors about the negative impacts of a failed FDA inspection at its facility in India, which has affected its financial performance.
	2025-04-15	+0.56 %
The article discusses a notification from The Gross Law Firm to shareholders of Viatris Inc. (VTRS) regarding a class action related to misleading statements about a failed FDA inspection, which previously caused a significant decline in the stock price. The slight increase of 0.56% in VTRS stock may be attributed to shareholders anticipating a recovery from the legal actions or potential positive developments following the initial fallout from the inspection news. The article reports that Viatris Inc. (VTRS) stock increased by 0.56% amid ongoing class action litigation alleging securities fraud related to the company's financial disclosures and the impact of regulatory issues on its future prospects. The stock's increase may be attributed to market reactions to the legal proceedings and perhaps optimism regarding future resolutions or buyer interest despite the class action lawsuit. Ventas, Inc. (NYSE: VTR) stock rose by 0.56% following a series of positive ratings and increased price targets from various analysts, indicating strong market confidence in the company's future performance. The article reports that the stock of Viatris Inc. (VTRS) rose by 0.56% despite a recent class action lawsuit alleging that the company misled investors about the impact of regulatory issues, likely due to a broader market trend or investor sentiment recovering after the sharp price decline following the lawsuit announcement. Ventas (VTR) stock rose by 0.56%, attributed to investor sentiment and potential legal actions related to Viatris, which may have shifted focus away from VTR amidst concerns over Viatris's handling of an FDA inspection and subsequent financial disclosures.
	2025-04-14	+1.95 %
Ventas (VTR) stock rose 1.95% last night, likely due to strong institutional ownership, which indicates a positive long-term outlook from large investors, despite its lower valuation compared to Simon Property Group. Ventas (VTR) stock rose 1.95% amid positive earnings news and increased analyst ratings, despite significant selling by some institutional investors. The article discusses how Viatris Inc. (NASDAQ:VTRS) stock recently increased by 1.95%, likely due to its favorable placement among the top healthcare stocks recommended by billionaire investor David Einhorn. Ventas (VTR) stock increased by 1.95% amidst a broader market sell-off, driven by a growing investor focus on the defensive healthcare sector as concerns about a potential recession and ongoing trade wars encourage a shift away from riskier equities.
	2025-04-11	+0.78 %
The article discusses a class action lawsuit against Viatris Inc. (NASDAQ: VTRS) due to misleading statements about the company's financial outlook following detrimental inspection results from the FDA, which negatively impacted investor confidence. The increase in Vistra's (VTR) stock by 0.78% may be attributed to broader market trends, recovery from previous declines, or investor speculation surrounding potential resolutions to the issues raised in the lawsuit. Ventas (VTR) stock rose by 0.78% amid news of a lawsuit filed against Viatris Inc. for alleged securities fraud, which may have led investors to view the situation as an opportunity to buy into stocks perceived as undervalued after the recent decline in Viatris's stock price.
	2025-04-10	+0.02 %
The article informs investors about a class action lawsuit against Viatris Inc. (NASDAQ: VTRS) related to alleged securities fraud affecting stock prices after the company's disappointing financial guidance following an FDA warning letter. Ventas (VTR) stock's increase of 0.02% might be attributed to broader market trends or investor sentiment, as specific reasons for VTR's price movement are not detailed in the article concerning Viatris.
	2025-04-09	+3.55 %
Ventas (VTR) stock rose by 3.55% due to ongoing interest in the company amidst legal activity discussed in a notice from The Gross Law Firm regarding potential investor recoveries related to Viatris Inc., although specifics about the reasons for VTR's increase were not provided in the article. Ventas, Inc. (NYSE:VTR) saw a 3.55% increase in its stock price, likely driven by the announcement of a higher quarterly dividend and positive analyst ratings, despite the CEO's recent sale of shares. Ventas (VTR) stock rose 3.55% following a significant class action lawsuit being filed against Viatris, which may have prompted investor interest and confidence in VTR's relative stability amidst Viatris' troubles. Ventas (VTR) stock rose by 3.55% amidst the news of a class action lawsuit filed against Viatris Inc. regarding misrepresentation of its operational challenges, potentially indicating investor confidence in VTR as a safer investment in light of Viatris' difficulties. The increase in VTR stock could be attributed to investors shifting focus to companies perceived as more stable or resilient amid negative news surrounding Viatris, suggesting a reallocation of investments toward Ventas. The article discusses a lawsuit filed against Viatris Inc. for potential securities law violations, which has affected the stock price, but Venta's (VTR) stock rose by 3.55% likely due to market reactions to broader investor sentiments or technical factors unrelated to the lawsuit against Viatris.
	2025-04-07	-2.06 %
Ventas (VTR) stock declined by 2.06% due to investor concerns stemming from a class action lawsuit against Viatris Inc. (VTRS) regarding undisclosed issues related to the failed inspection of its Indore, India facility, which negatively affected financial results. Ventas (VTR) stock fell by 2.06% due to an investigation into allegations of securities fraud and unlawful business practices related to Viatris Inc., which has negatively impacted investor confidence following the company's disappointing fourth-quarter financial results and lowered guidance for 2025. Ventas (VTR) stock experienced a decline of 2.06% due to ongoing concerns surrounding Viatris, Inc., including a recently filed class action lawsuit alleging securities fraud and the company's poor financial performance and lower guidance, which has negatively impacted investor confidence. Ventas (VTR) stock declined by 2.06% following a lawsuit against Viatris Inc. for potential securities fraud, which revealed significant issues stemming from a failed FDA inspection that negatively impacted the company's financial outlook.
	2025-04-04	-5.88 %
Ventas (VTR) stock fell by 5.88% following disappointing financial results and guidance related to issues with Viatris Inc.'s Indore facility, which were misrepresented by the company and led to a significant drop in investor confidence. Ventas, Inc. (VTR) stock fell by 5.88% primarily due to a mix of insider selling and varying analyst ratings, despite relatively strong quarterly earnings data and a raised dividend.
	2025-03-28	+1.16 %
Ventas Inc. (NYSE:VTR) experienced a 1.16% increase in its stock price, reaching $68.76, following a year-long gain of 60.43%, despite a slight decline of 0.61% in the past month. The rise in VTR stock may be attributed to positive market sentiment or developments that have potentially improved investor confidence in the company's future performance.
	2025-03-27	-0.31 %
Ventas (VTR) stock experienced a decline of -0.31% due to an ongoing investigation by Rosen Law Firm into potential securities claims related to misleading business information issued by Viatris Inc., which has faced significant financial repercussions from FDA warnings affecting its manufacturing facility. Ventas (VTR) stock declined by 0.31% due to recent selling by institutional investors, including Envestnet Portfolio Solutions cutting its holdings by 12%, despite a strong earnings report and an increased dividend announcement. Ventas (VTR) stock fell by 0.31% due to concerns over Viatris Inc.'s recent financial results, which missed estimates and included lower-than-expected guidance, along with ongoing issues related to a manufacturing facility under FDA scrutiny. Ventas (VTR) stock declined by 0.31% amid recent market activity, despite institutional investors increasing their stakes and positive earnings reports. The stock may have fallen due to a combination of insider sales, including CEO shares, and market fluctuations influenced by recent analyst adjustments to price targets.
	2025-03-24	+2.03 %
Ventas (VTR) stock rose by 2.03% due to the preference for dividend-paying stocks among investors seeking stable income and reduced volatility amidst current market uncertainties.
	2025-03-21	-1.27 %
Ventas (VTR) stock declined by 1.27%, possibly due to market fluctuations or specific company-related news, while analysts predict significant growth in consumer spending driven by the aging population, positioning companies like VTR for potential long-term benefits in the evolving market. Ventas, Inc. (NYSE: VTR) saw a decline of 1.27% in stock price, potentially influenced by reduced positions from institutional investors like Farther Finance Advisors LLC, which lowered its holdings by 13.9%, alongside insider selling activities. Ventas (NYSE: VTR) stock fell by 1.27% last night despite a consensus recommendation of "Moderate Buy" from analysts, likely influenced by insider selling and market volatility, as indicated by recent transactions involving CEO Debra A. Cafaro and other insiders.
	2025-03-20	+0.19 %
The article announces an investigation by Rosen Law Firm into potential securities claims against Viatris Inc. (NASDAQ: VTRS) due to allegations of misleading business information, following a significant drop in their stock price after a concerning financial disclosure. Ventas (VTR) stock increased by 0.19% likely due to investor optimism or reactions to external market factors unrelated to Viatris, as the article primarily focuses on Viatris rather than Ventas specifically. Ventas (NYSE: VTR) stock increased by 0.19% following an upgrade of its price target by Mizuho from $68.00 to $75.00, with the firm maintaining an "outperform" rating, suggesting strong investor confidence and potential upside for the stock.
	2025-03-19	-0.89 %
Ventas (VTR) stock fell by 0.89% due to concerns following Viatris Inc.'s fourth quarter and full year 2024 financial results, which missed expectations and included lower-than-expected guidance for 2025, along with ongoing remediation issues at a manufacturing facility.
	2025-03-18	-0.81 %
Ventas (VTR) stock declined by -0.81% following analysts' favorable comparisons between Ventas and Douglas Emmett (DEI), indicating that DEI is viewed as a better investment due to its higher potential upside and better dividend yield, leading investors to prefer DEI over VTR.
	2025-03-17	+2.78 %
Ventas (VTR) stock rose 2.78% last night and has shown strong performance over the past five years, outperforming the market by 5.99% annually, primarily due to a solid average annual return of 25.76% and a substantial market capitalization of $29.24 billion. The increase in Ventas (VTR) stock can be attributed to its strong historical performance and investor confidence in the company's continued growth prospects. Ventas (VTR) stock rose by 2.78% due to increased institutional investment and positive analyst ratings, including a "strong-buy" upgrade and target price boosts from firms like Wells Fargo.
	2025-03-14	+0.8 %
Ventas (VTR) stock increased by 0.8% recently, likely driven by significant investments from institutional investors, positive analyst upgrades, and strong quarterly earnings that exceeded expectations.
	2025-03-13	+0.02 %
Ventas (NYSE: VTR) stock increased by 0.02% following analysts at Morgan Stanley raised its target price from $65.00 to $70.00, indicating a potential upside and reflecting positive sentiment among various brokerage firms that have issued upgraded ratings and target price increases for the company. Ventas, Inc. (NYSE: VTR) experienced a slight increase of 0.02% in stock price, influenced by recent institutional investments, including Edgestream Partners L.P.'s acquisition of 11,265 shares, and positive earnings reports that exceeded analyst expectations.
	2025-03-12	-0.52 %
Ventas (VTR) stock fell by 0.52% to $67.75 amid lower trading volume compared to average levels, and its high price-to-earnings ratio indicates it may be viewed as overvalued, potentially contributing to the stock's decline.
	2025-03-11	-1.2 %
Ventas (VTR) stock experienced a decline of 1.2% on the previous night, despite a recent increase in target price by Wells Fargo and positive analyst ratings, likely due to profit-taking from insiders selling shares and mixed signals from other analysts regarding future price targets.
	2025-03-10	-0.53 %
Ventas (NYSE: VTR) stock declined by 0.53% despite a target price increase by various analysts, which may be attributed to recent insider selling and mixed analyst ratings.
	2025-03-05	+0.95 %
The article discusses Faruqi & Faruqi LLP's investigation into potential claims against Viatris Inc. (NASDAQ: VTRS) following significant financial losses reported by the company. The increase in Viatris stock by 0.95% may be attributed to market recovery or investor sentiment after a drop following disappointing earnings and guidance, suggesting that traders might view the recent decline as an opportunity to buy at a lower price.
	2025-02-28	+0.76 %
The article discusses Nxera Pharma's agreement with Viatris Inc. and Idorsia Pharmaceuticals to develop and commercialize the immunology candidate cenerimod in the Asia-Pacific region, which is expected to enhance Nxera's value and may positively influence the stock price of Viatris (VTR), leading to a 0.76% increase.
	2025-02-27	+0.56 %
Ventas (VTR) stock rose by 0.56% recently, reaching $68.28, as part of a trend where growth stocks, particularly those focused on senior housing and health care infrastructure, are gaining attention due to their potential to deliver strong returns amid a growing aging population.
	2025-02-21	-1.15 %
Ventas (VTR) stock fell by 1.15%, despite receiving an overall "Buy" rating from analysts and positive earnings, primarily due to selling by insiders and fluctuating price targets from different brokerages which may have influenced investor sentiment negatively.
	2025-02-20	-0.16 %
Ventas (VTR) stock declined by 0.16% following a significant reduction in holdings by Blue Trust Inc., which sold nearly half of its shares in the company, raising concerns about institutional investor confidence.
	2025-02-19	+0.28 %
Ventas (VTR) stock rose by 0.28% following increased institutional investment, with significant purchases made by Vontobel Holding Ltd. and other hedge funds, indicating strong confidence in the company.
	2025-02-18	+0.36 %
Ventas (VTR) stock rose by 0.36% following positive earnings forecasts from analysts at Wedbush, who estimated an increase in earnings per share to $3.72 for FY2026, along with several upgrades from other research firms recommending a buy or strong buy rating.
	2025-02-12	+0.62 %
Ventas (VTR) stock rose by 0.62% due to positive investor sentiment influenced by overall market dynamics, as indicated by a general trend of net inflows into equity mutual funds despite existing market volatility. Ventas (VTR) stock rose by 0.62% as several institutional investors increased their stakes in the company, reflecting positive sentiment and confidence in its growth prospects as a real estate investment trust focused on senior housing solutions. The article notes that Ventas (VTR) stock rose by 0.62% last night amid a mixed market performance influenced by various corporate earnings reports and macroeconomic factors. The increase in Ventas (VTR) stock is likely due to positive investor sentiment or specific favorable developments related to the company that were not detailed in the provided text.
	2025-01-30	+0.94 %
Ventas, Inc. (NYSE:VTR) has received a consensus "Buy" recommendation from analysts, contributing to a 0.94% increase in its stock price, driven by positive changes in ratings and price objectives from several research firms. Ventas, Inc. (NYSE: VTR) experienced a 0.94% increase in stock price due to significant institutional investment activities, with multiple firms boosting their stakes and positive ratings from research analysts alongside a recently announced quarterly dividend.
	2025-01-27	+1.64 %
Ventas (VTR) stock rose by 1.64% as Atomi Financial Group Inc. and other institutional investors increased their holdings in the company, indicating growing investor confidence and demand for the stock.
	2025-01-24	+2.32 %
Ventas (VTR) stock rose 2.32% due to increased institutional investment and positive analyst ratings, indicating strong confidence in the company's growth potential and solid dividend payments.
	2025-01-23	+1.85 %
Ventas (VTR) stock rose 1.85% due to strong institutional ownership and positive analyst expectations, with a consensus price target suggesting a potential upside of 15.04% for the company.
	2025-01-21	+2.36 %
Ventas (VTR) stock rose by 2.36% following a significant increase in institutional investments, including a 32% stake boost by Merit Financial Group, positive analyst ratings updates, and the announcement of a quarterly dividend.
	2025-01-16	+0.53 %
Ventas (VTR) stock rose by 0.53% due to increased institutional investment and positive analyst ratings, as the Czech National Bank raised its position in the company by 8.1% while other firms also enhanced their stakes in the REIT. Ventas, Inc. (NYSE: VTR) stock experienced a 0.53% increase last night, primarily due to significant institutional investments in the company, including a notable 66.2% increase in holdings by Harbor Capital Advisors and other large investors buying new stakes during the recent quarters. The article discusses the performance of Viatris Inc. (NASDAQ:VTRS), which experienced a 2.82% drop in share prices on Wednesday, contrary to the positive performance of broader market indices, primarily due to investor sell-offs triggered by concerns about the stock being oversold, along with negative developments such as the planned closure of its manufacturing plant by 2028. Ventas (VTR) stock has not been discussed in this article, so we cannot determine why its stock price went up based on this content.
	2025-01-15	-0.09 %
Ventas (VTR) stock recently declined by 0.09% as the market reacts to rising yields on the 10-year Treasury note, which typically negatively impacts REITs due to their nature as "bond proxies" that compete with fixed-income investments for investor attention.
	2025-01-06	-2.42 %
Ventas (VTR) stock fell by 2.42% following a report that Pensionfund DSM Netherlands reduced its holdings in the company by 20.1%, selling 17,000 shares, which may have triggered negative sentiment among investors.
	2024-12-23	+0.29 %
Ventas (NYSE: VTR) stock increased by 0.29% after analysts upgraded its rating from "sell" to "hold" and several other firms expressed positive sentiments, raising price targets and outlooks for the company.
	2024-12-19	-1.65 %
Ventas (VTR) stock was down by 1.65% as institutional investors, including MML Investors Services LLC and UBS AM, continued to adjust their stakes in the company, and notable insider selling by CEO Debra A. Cafaro may have raised concerns about management confidence or stock valuation. Ventas (VTR) stock has declined by 1.65%, possibly due to its high projected earnings multiple, positioning it as one of the most expensive stocks in the S&P 500 and reflecting investor caution amid market volatility and competition among emerging tech stocks.
	2024-12-18	-2.52 %
Ventas (VTR) stock fell by 2.52% after the CEO sold a significant portion of their shares, alongside mixed signals from analysts regarding the stock's outlook. The stock's decline could be attributed to investor concerns stemming from the CEO's sale, which may create uncertainty about the company's future performance.
	2024-12-16	-0.72 %
Ventas (VTR) stock declined by 0.72% after StockNews.com downgraded it from a hold to a sell rating, which reflects a bearish outlook among analysts.
	2024-12-12	-1.12 %
Ventas (VTR) stock fell by 1.12% due to a reduction in holdings by Integrated Wealth Concepts LLC and the general movement of institutional investors adjusting their stakes in the company.
	2024-12-10	+0.15 %
Ventas (VTR) stock increased by 0.15% last night as several hedge funds adjusted their positions, with some buying more shares, which could indicate positive sentiment towards the stock amid favorable analyst ratings and a stable company performance in the real estate investment sector.
	2024-12-06	-0.77 %
Ventas (VTR) stock declined by 0.77%, despite an outperform rating from Wedbush and revised earnings estimates, possibly due to recent insider selling and general market conditions impacting investor sentiment.
	2024-12-04	-1.02 %
Ventas (VTR) stock fell by 1.02% due to analysts favoring Global Self Storage (SELF) over Ventas, citing better potential upside, more sustainable dividend payments, and various performance metrics where Global Self Storage had an edge.
	2024-11-26	+1.66 %
Ventas (VTR) stock rose 1.66% last night, attributed to positive momentum following a series of institutional investments, favorable analyst upgrades, and the company's focus on senior housing, amidst ongoing modifications in ownership by institutional investors. Ventas, Inc. (NYSE:VTR) stock increased by 1.66% due to positive ratings and target price upgrades from several analysts, reflecting confidence in the company's performance amidst changes in institutional holdings.
	2024-11-22	-1.17 %
Ventas (VTR) stock experienced a decline of 1.17% as institutional investors are adjusting their holdings, alongside recent insider selling by key executives which may contribute to investor uncertainty.
	2024-11-19	+0.61 %
Ventas (VTR) stock rose by 0.61% due to increased institutional investments, favorable upgrades in analysts' ratings, and the company's strategic focus on the growing senior housing market.
	2024-11-13	-0.05 %
Ventas (VTR) stock decreased by 0.05% amid various institutional modifications in holdings and insider sales, which may signal a lack of confidence or trigger uncertainty among investors. Ventas (VTR) stock experienced a slight decline of 0.05% possibly due to insider selling, as CEO Peter J. Bulgarelli and other executives sold shares recently, which can lead to investor concern about the company’s outlook and confidence from leadership.
	2024-11-08	+1.09 %
Ventas, Inc. (NYSE: VTR) saw a 1.09% rise in its stock price following various analysts' ratings upgrades and target price increases, despite a revised downward earnings estimate from Wedbush.
	2024-11-06	-1.94 %
Ventas (VTR) stock fell by -1.94% due to a significant reduction in its position by the New York State Common Retirement Fund, which sold 43,100 shares, along with other institutional investors altering their stakes in the company during the third quarter.
	2024-11-04	+0.25 %
Ventas (VTR) stock rose by 0.25% following new institutional investments and positive analyst ratings upgrades, reflecting increased confidence in the company's growth prospects in the senior housing sector. Ventas (VTR) stock increased by 0.25% due to an upgrade from a sell to a hold rating by StockNews.com and positive revisions to price targets and ratings from several analysts, indicating increased investor confidence in the company's prospects.

1
500 / page